US trade representative Michael Froman in a meeting with Indian commerce minister Anand Sharma today raised concerns about recent developments in climate for Intellectual Property Rights (IPR) protection in India, reports Rituparna Bhuyan.
Froman made indirect references to the developments regarding the Novartis as ell as the Bayer case. In April Supreme Court had rejected Swiss pharma firm Novartis' patent plea for Glivec. While in case of Bayer, IPAB had ruled in March that the Indian government was within its rights in issuing a compulsory licence allowing the manufacture of affordable generic versions of Bayer’s patented drug.
Froman also raised concern about preferential treatment given to indigenous IPR in India and claimed that treatment favoured domestic manufacturers, suppliers.
He also told Sharma that it was possible to promote access to medicines without stifling innovation. He appreciated India's move to put the preferential market access for electronic goods. He also discussed India's concerns regarding the Immigration Bill. It remains to be seen if all this dialogue that happened today will lead into any concrete moves as far as the US Immigration Bill is concerned.